Obermatt

Jazz Pharmaceuticals

NSQ:JAZZ · IE00B4Q5ZN47
PharmaceuticalsLarge

360

91
EV / EBIT87
Price / Owner Earnings50
Owner Earnings Yield53
Dividend Yield1
Price/Sales50
EV / Gross Profit71
Price/Book61
Return on Capital49
Cash Return on Capital47
Return on Equity17
EBIT Margin84
Gross Profitability37
Cash Conversion100
Accruals56
Owner Earnings Margin57
Sales growth46
Profit Growth73
Long-Term EPS Growth100
Owner Earnings Growth93
Reinvestment15
Price momentum98
Debt load9
Refinancing67
Debt Payback23
Liquidity40
Analyst ratings56
Opinion Changes87
Price Target Upside40
Market mood25
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Jazz Pharmaceuticals clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryIreland
IndustryPharmaceuticals
SizeLarge
TypePublic Company
ExchangeNASDAQGS
Founded2005
Employees2,836
ISINIE00B4Q5ZN47
Last UpdateApr 2, 2026
Themes
NeuroscienceCentral Nervous SystemOncologyHematologySleep TechnologyNeurologyCannabisGenetics

Description

Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) operates as a biopharmaceutical company. The company is dedicated to developing life-changing medicines for people with rare diseases—often with limited or no therapeutic options. The company has a div…

Analysis

Middle-of-the-road

Jazz Pharmaceuticals plc is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is fair. You pay 21.8× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 7% yearly growth; analysts expect 55%. The price, in other words, assumes less than the experts do.

The trajectory is solid and the balance sheet is adequate. The company scores 12/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
71
2023202420252026

All-time high

87

Feb 2026

All-time low

38

Jan 2023

Average rank

64

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
50
48
52
56
Price/Earnings
51
97
94
90
Price/Book
61
44
48
62
Dividend Yield
1
1
1
1
Value (overall)
41
53
47
62

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Jazz Pharmaceuticals with its peers
GSK
LSE:GSK
72
CountryUK
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Pharvaris
NSQ:PHVS
38
CountryNetherlands
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Avadel Pharmaceuticals
NMQ:AVDL
70
CountryIreland
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
BioVersys
SWX:BIOV
11
CountrySwitzerland
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Newron Pharmaceuticals
SWX:NWRN
15
CountryItaly
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Immunocore
NSQ:IMCR
40
CountryUK
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →